Original Research

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

Yang QM, Hong JY, Ko YH, Lin SY, Au WY, Choi MK, Park S, Kim SJ, Kim WS

OncoTargets and Therapy 2014, 7:1717-1722

Published Date: 26 September 2014